FyoniBio and Strike Pharma sign a Master Service Agreement covering Cell Line Development for a novel bi-specific therapeutic mAb
Berlin, Germany and Stockholm, Sweden, October 20, 2022: FyoniBio, a CDO expert specialized in tailored cell line development and Strike Pharma, whose proprietary Adaptable Drug Affinity Conjugate (ADAC) technology enables development of individualized immunotherapeutic treatments, are pleased to announce the signing of a cell line development agreement for Strike Pharma`s novel, innovative therapeutic recombinant mAb candidate. weiter
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
SAN FRANCISCO and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced it has dosed the first patient in the IMAG1NE Phase 1/2 clinical trial. The IMAG1NE trial is designed to evaluate the safety and preliminary efficacy of TK-8001, a T cell receptor (TCR) engineered T cell therapy (TCR-T) specific for the Melanoma-associated Antigen Gene-A1 (MAGE-A1), in patients with solid tumors. weiter
With patience and a green thumb
Viola Ehrig is the green-thumbed gardener who works hard to ensure it’s not only science and innovation that flourish at the Berlin-Buch campus, but trees and flowers as well. She and her colleague Steve Kossack provide stimulating surroundings for everyone at the science campus, including employees of the MDC. weiter
Where science turns into business
On April 25, 2022, Federal Commissioner for East Germany, Minister of State Carsten Schneider, and Governing Mayor of Berlin Franziska Giffey visited Campus Berlin-Buch to see how the “Zukunftsort” (place of the future) is developing. weiter
